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Abstract  23 
According to the FAO/WHO, the survival to gastrointestinal tract (GIT) challenges 24 
and the ability to colonize the colon are some of the in vitro tests proposed for the selection of 25 
probiotics for food application. We have used a model that simulates the GIT transit using 26 
immersion in, sequentially, gastric and duodenal juices from human origin to evaluate the 27 
survival of bile-adapted Bifidobacterium strains. Bifidobacterium animalis tolerated well the 28 
gastric juice, whereas Bifidobacterium longum showed poor survival in these conditions. In 29 
contrast, B. animalis strains were more sensitive to duodenal juice than B. longum. The 30 
percentage of survival after the GIT transit simulation (GITTS), determined both with plate 31 
counts and fluorescent probes, was significantly higher for the bile-adapted strains than for 32 
the corresponding parental ones. This suggests that the use of bile-adapted strains is a suitable 33 
approach to increase the survival of bifidobacteria to the harsh conditions of the upper GIT. 34 
However, the bile-resistance phenotype was not related with any improvement in the adhesion 35 
capability, after GITTS, to the intestinal cell line HT29-MTX which constitutively produces 36 
mucus. This work shows that the sequential GITTS with human juices modified the in vitro 37 
adhesion properties of the challenged strains to colonocyte-like cells. 38 
 39 
Key-words: bifidobacteria; bile-adapted strain; human gastric juice; human duodenal juice; 40 
HT29-MTX cell line; gastrointestinal transit simulation (GITTS). 41 
42 
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1. Introduction 43 
 Probiotics have been defined as “live microorganisms which, when administered in 44 
adequate amounts confer a health benefit on the host” (FAO/WHO, 2006), with 45 
Bifidobacterium and Lactobacillus being the genera most commonly found in probiotic dairy 46 
products for human consumption (Gueimonde et al., 2004; Masco et al., 2005). When 47 
ingested, these bacteria must overcome the gastrointestinal tract (GIT) barrier in sufficient 48 
numbers to arrive in the colon or in a metabolically active state, in order to transitorily persist 49 
in this environment, thus being able to exert their healthy effects. The extremely low pH 50 
(ranging from 1.5 to 3) and gastric enzymes in the stomach, followed by the bile salts, 51 
pancreatin and other intestinal enzymes that bacteria find in the duodenum, are the main 52 
challenges for probiotics (Masco, et al., 2007). One of the strategies to improve the microbial 53 
viability in these harsh conditions is the use of acid- and/or bile-resistant bacteria (Chung, et 54 
al., 1999; Collado and Sanz, 2006). We have previously obtained a collection of bile-adapted 55 
strains by exposure of parental strains to progressively increasing concentrations of bile salts 56 
(Margolles et al., 2003; Noriega et al., 2004). Some of these adapted strains have even several 57 
improved in vitro properties with respect to the parental strains, such as increased adhesion to 58 
human mucus (Gueimonde et al., 2005) and inhibition of pathogen adhesion (Gueimonde et 59 
al., 2007).   60 
Several publications have reported the survival of different probiotic strains to the 61 
simulated conditions of the GIT, using chemically semi-defined gastrointestinal juices (de 62 
Palencia et al., 2008; Huang and Adams, 2004; Mainville et al., 2005; Masco et al., 2007). 63 
Recently, Mozzi et al. (2009) simulated the transit through the mouth using human saliva and 64 
Del Piano et al. (2008) tested the resistance of probiotics to human pancreatic juice. However, 65 
to the best of our knowledge, no data are currently available simulating GIT transit with 66 
sequential use of human gastric and duodenal juices. On the other hand, several authors have 67 
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studied the possible colonization ability of putative probiotic strains by analysing their 68 
adhesion capability to epithelial intestinal cell lines, such as Caco-2 and HT29 (Candela et al., 69 
2008; Riedel et al., 2006; Schillinger et al., 2005). A limitation of these studies is that the 70 
survival of strains after the GIT transit is assessed by simulation with independent gastric and 71 
duodenal juices tests. In addition, as far as we know, there is no information about the 72 
influence of GIT transit simulation (GITTS) on the subsequent adhesion ability of probiotic 73 
strains.  74 
Taking into account these facts, the aim of the present study was to evaluate whether 75 
the acquisition of resistance to bile could influence the survival and adhesion ability of 76 
bifidobacteria under the GIT conditions simulated in vitro. For this purpose, bifidobacteria 77 
were challenged in a model of GITTS using, sequentially, gastric and duodenal juices from 78 
human origin and finishing with the study of their adhesion capability to the epithelial 79 
intestinal cell line HT29-MTX, which is able to constitutively produce mucin (Lesuffleur et 80 
al., 1990).   81 
 82 
2. Material and Methods  83 
2.1. Bacterial strains and growth conditions 84 
Three groups of parental and bile-adapted derivative Bifidobacterium strains have 85 
been used in this study (Gueimonde et al., 2005; Noriega et al., 2004), as indicated in Table 1. 86 
Bacteria were cultured in MRSC [MRS (Biokar Diagnostics, Beauvais, France) with 0.05% 87 
(w/v), L-cysteine (Sigma Chemical Co., St. Louis, MO)] and incubated for 24 h at 37ºC in an 88 
anaerobic chamber MG500 (Down Whitley Scientific, West Yorkshire, UK) under 10% (v/v) 89 
H2, 10% CO2 and 80% N2.     90 
2.2. Collection of human gastric and duodenal juices  91 
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The collection of the human samples was approved by the Regional Ethics Committee 92 
of Clinical Research from the Principado de Asturias (Spain) after the informed consent form 93 
was signed by the volunteers. Samples were obtained from 16 donors (7 male and 9 female 94 
from 25 to 67 years old) that needed an endoscopic exploration of the upper GIT (oesophagus, 95 
stomach and duodenum) due to unspecific digestive disturbances. They had not any previous 96 
intestinal pathology or surgery, were not taking acid secretion inhibitors or antibiotic 97 
treatment and declared as following a healthy diet. After the endoscopic study, they did not 98 
show pathology and thus they were considered as healthy donors. The endoscopy was 99 
performed after 6 hours without liquid or food intake using a video-endoscope Olympus GIF-100 
Q 165 (Olympus Europa GmbH, Hamburg, Germany). The gastric juice (GJ) and duodenal 101 
juice (DJ) were aspired through the endoscope after its location into the gastric body or the 102 
duodenal bulb, respectively. The DJ collected from the duodenal bulb contained gall bladder, 103 
pancreatic and duodenal secretions.   104 
For each donor, the 3 ml initially aspired was discarded and the resting juice was 105 
collected in a sterile tube which was stored at -20ºC until use. The pH of the GJ samples 106 
ranged from 1.4 to 2.5 and that of DJ samples from 7.4 to 8.6. Samples of GJ and DJ from 107 
different donors were mixed (giving a final pH of 1.6 and 7.5, respectively) and were filtered 108 
through 0.45 μm sterile PTFE-membrane filters (VWR International Eurolab S.L., Barcelona, 109 
Spain) before use. 110 
2.3. Survival to the simulated gastrointestinal transit 111 
 The simulation of the GIT transit is outlined in Fig. 1. Bacterial cultures were 112 
centrifuged (10,000 × g, 10 min), washed twice with sterile saline solution (0.85% NaCl), 113 
resuspended in 20% of sterile skimmed-milk (Difco, Becton Dickinson, Franklin Lakes, NJ) 114 
and added to GJ which increased the pH of the mixture from 1.6 to 1.9. To simulate 115 
conditions in the stomach, bacterial suspensions were kept at 37ºC under middle stirring (200 116 
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rpm) for 90 min (step 1). Afterwards, and to simulate the duodenal conditions, bacteria were 117 
collected by centrifugation, resuspended in DJ and kept under anaerobic conditions for 20 min 118 
(step 2). Finally, harvested bacteria were resuspended in diluted DJ (dDJ: DJ diluted 10-fold 119 
in saline solution) and kept for 18 h under anaerobiosis (step 3). This last step simulates 120 
conditions of the distal part of the small intestine. The experiments were carried out in 121 
triplicate for each strain.  122 
 Initially, and after each step, samples were taken to determine bacterial counts (CFU 123 
ml-1). Serial dilutions were made in Ringer’s solution (Merck, Darmstadt, Germany), pour-124 
plated in agar-MRSC and plates incubated at 37ºC under anaerobic conditions for 72 h.  125 
Additionally, after step 2 bacterial suspensions were collected and dyed with the Live/Dead® 126 
BacLigth bacterial viability kit (Molecular Probes, Invitrogen, Merck) following the 127 
manufacturer’s instructions. Fluorescence emitted (512 nm for green probe and 620 nm for 128 
red probe) by cells after samples excitation at 470 nm was measured in a Cary Eclipse 129 
fluorescence spectrophotometer (Varian Ibérica S.A., Madrid, Spain). The ratio between 130 
(cultivable and non-cultivable) viable (green) and dead (red) bacteria was used to calculate the 131 
percentage of survival after the GIT transit. The correlation coefficient of the calibration 132 
survival curves was 0.993±0.003.   133 
2.4. Adhesion to the cell line HT29-MTX 134 
 Bacterial suspensions were collected after step 3 of the GITTS to assess their 135 
capability to adhere to the epithelial intestinal cell line HT29-MTX. Additionally, bacterial 136 
suspensions harvested from MRSC cultures grown for 24 h were used to assess the adhesion 137 
ability of the strains not submitted to the GIT challenge. The cell line was maintained in 138 
Dulbecco´s modified Eagle´s medium (DMEM) supplemented with 10% (v/v) heat-139 
inactivated foetal bovine serum and a mixture of antibiotics to give a final concentration of 50 140 
μg ml-1 penicillin, 50 μg ml-1 streptomycin, 50 μg ml-1 gentamicin and 1.25 μg ml-1 141 
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amphotericin B. All media and reagents were purchased from Sigma. HT29-MTX cells 142 
(1x105 cells ml-1) were seeded in 24-well plates and incubated to confluence (about 1x107 143 
cells ml-1) for 14±1 days at 37ºC, 5% CO2 in an SL Waterjacked CO2 Incubator (Sheldon 144 
Mfg. Inc., Cornelius, Oregon). Experiments were carried out using two independent HT29-145 
MTX plates (two consecutive passes) and in each plate bacterial strains were analysed by 146 
duplicate. The reproducibility of data, determined by calculating the coefficient of variation 147 
[(SD*100)/mean], was on average 19%.   148 
Bacterial suspensions were harvested (10,000 × g, 15 min), washed twice with 149 
Dulbecco’s PBS buffer (Sigma) and resuspended in DMEM without antibiotics at a ratio of 150 
about 10:1 (bacteria : eukaryotic cell, respectively). HT29-MTX monolayers were washed 151 
twice with Dulbecco’s PBS to remove the antibiotics before adding the bacterial suspension 152 
and then plates were incubated for 1 h at 37°C, 5% CO2 in a Heracell® 240 incubator 153 
(Thermo Electron LDD GmbH, Langenselbold, Germany). After the incubation period, 154 
supernatants were removed and the wells were softly washed three times with Dulbecco’s 155 
PBS buffer to remove the non-attached bacteria. Finally, the HT29-MTX monolayers were 156 
trypsinised with 0.25% trypsin-EDTA solution (Sigma) following standard procedures. The 157 
adhesion percentage was calculated using the quotient “bacteria adhered with respect to the 158 
bacteria added”. For strains not submitted to the GIT challenge (cultured in MRSC), bacteria 159 
were enumerated by plate counting (CFU ml-1) as previously described (Sanchez et al., 2010). 160 
According to the results of GITTS survival, the level of non-cultivable but still viable bacteria 161 
could be high in the cultures submitted to the GIT challenge. Thereby, to determine the 162 
adhesion of strains submitted to the GIT transit, bacterial loads (bacteria ml-1) were 163 
determined under optical microscope by using a Neubauer counting chamber (Brand, VWR 164 
International Eurolab) which allowed us to enumerate both the cultivable and non-cultivable 165 
bacteria.   166 
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2.5. Statistical analysis 167 
All experiments have been carried out at least in triplicate. Data were statistically 168 
analysed using the SPSS 11.0 software for Windows (SPSS Inc., Chicago, IL). Within each 169 
parental / derivative setof strains, independent one-way ANOVA tests were performed to 170 
determine differences among strains. For the triad A1, A1dOx and A1dOx-R1, the mean 171 
comparison LSD (least significant difference, p< 0.05) test was additionally used.  172 
 173 
3. Results and Discussion 174 
According to the guidelines of the FAO/WHO (2006) the resistance to the adverse 175 
GIT conditions and the ability to adhere to human epithelial intestinal cells are some of the in 176 
vitro tests recommended for the selection of probiotic bacteria before studying their in vivo 177 
functionality by means of animal models and/or human interventions trials. In this work we 178 
have tested in vitro the behaviour of bile-adapted bifidobacteria strains under the GITTS 179 
conditions by using human gastric and duodenal juices and the human epithelial intestinal cell 180 
line HT29-MTX. Figure 2 depicts the evolution of bifidobacteria counts during the simulated 181 
GIT transit. The survival of the bacteria in the human juices was dependent on the strain. 182 
Counts of both strains of Bifidobacterium longum decreased drastically after the GJ challenge 183 
(4.61±2.07 and 2.5±1.50 log CFU ml-1 units for the parental and bile-adapted strains, 184 
respectively), whereas the count decrease of Bifidobacterium animalis strains did not reach 1 185 
log unit. Population levels of strains from both species remained without noticeable variations 186 
during the DJ (simulated duodenal conditions) challenge but, after 18 h in diluted DJ 187 
(simulating the distal part of the small intestine) the five strains of B. animalis showed the 188 
highest reduction in their counts, which was also much more pronounced than for B. longum. 189 
These results suggest that the B. longum strains are considerably less resistant to acidic 190 
conditions than the B. animalis ones, but considerably more tolerant than this last species to 191 
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the bile and/or enzymes present in the duodenal juice used in our experimental model. Similar 192 
findings were previously reported (Masco et al., 2007) indicating that B. animalis strains 193 
showed the highest resistance to chemical-gastric juice but a low tolerance to pancreatin as 194 
compared to other bifidobacteria species. It has also been demonstrated by proteomic 195 
approaches that, even when adaptation and response to bile and acid challenges in B. longum 196 
and B. animalis share common features, the expression of some proteins is differentially 197 
modified in each species depending on the stress conditions (Sánchez et al., 2008).  198 
Regarding the differences between our parental and bile-adapted strains, the final 199 
percentage of survival after the combined gastric-duodenal transit (step 2) determined with 200 
fluorescent probes (Fig. 3) showed statistically significant differences in favour of all bile-201 
adapted strains (p<0.05). In the case of the B. animalis A1-triad, only the strain A1dox-R1 202 
displayed nearly 100% survival after the simulated gastric-duodenal transit. This fact may be 203 
related to the putative protective role of a high molar mass (1.6x106 Da) exopolysaccharide 204 
(EPS) produced by this strain which is not present in the parental A1 and in the bile-adapted 205 
A1dOx strains (Ruas-Madiedo et al., 2010). In this way, several authors have suggested that 206 
bacterial EPS are involved in the protection against toxic compounds such as bile (Crawford 207 
et al, 2008; Hung et al., 2006; Ruas-Madiedo et al., 2009). Finally, as stated above for count 208 
evolution, the use of fluorescent probes also showed that B. longum had the poorest survival 209 
rate after gastric-duodenal transit.  210 
Figure 4 represents the percentage of adhesion to the human colon adenocarcinoma 211 
HT29-MTX cell line of our bifidobacteria strains not submitted to the GIT challenge (Fig. 4a) 212 
and after GITTS (step 3) using human juices (Fig. 4b). The adhesion capability of the strains 213 
not previously challenged was higher for the species B. animalis than for B. longum. Within 214 
the three groups of parental / derivative strains, the bile-adapted ones showed higher 215 
adherence capability to HT29-MTX line than their corresponding parental strains (significant 216 
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differences for strains A1dOx and 667Co, p<0.05). Similar behaviour was previously reported 217 
by us using a human intestinal mucus adhesion model (Gueimonde et al., 2005). In spite of 218 
this, B. animalis A1dOx-R1 presented a significant decrease in its adherence to the cell line 219 
with respect to both the parental A1 and the bile-adapted A1dOx strains. In this regard, we 220 
have demonstrated that the purified EPS A1dOx-R1 interferes in the in vitro adhesion of 221 
probiotic strains to human intestinal mucus (Ruas-Madiedo et al., 2006). Similarly, the 222 
deletion of the EPS-synthesis cluster in Lactobacillus johnsonii NCC533 increased the 223 
resident time of this strain in the gut of an in vivo murine model (Denou et al., 2008). On the 224 
other hand, and in contrast to that indicated above, after the GIT challenge the differences in 225 
adhesion between strains were much less evident (Fig. 4b) and the higher adherence of the 226 
bile-adapted strains in relation to the parental ones was not longer maintained. In fact, the 227 
strain 667Co even showed significantly lower adhesion than the corresponding parental strain 228 
NB667 (p<0.05). Changes in adhesion found in the parental and the bile-adapted strains after 229 
the GIT transit could be related to previously observed findings, which indicate that bile 230 
exposure modifies the surface characteristics of bifidobacteria (Noriega et al., 2004; Ruiz et 231 
al., 2007; Sánchez et al., 2008). Thus, the acquisition of the bile-resistance phenotype is not 232 
related to any improvement in the capability to adhere to colonocytes after the transit through 233 
the upper part of the gut. Finally, it is worth emphasising that in vitro test alone are not 234 
enough for supporting the in vivo functionality of the strains tested. Nevertheless, the use of in 235 
vitro intestinal cellular models, despite their limitations, provide a rational starting point for 236 
screening new potentially probiotic strains before enrolling in expensive and ethically 237 
compromised animal or human studies (Cencic and Langerholc, 2010). In any case, it is clear 238 
that to prove the safety and health benefits of a given strain, human intervention studies are 239 
required (FAO/WHO, 2006).     240 
 241 
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To conclude, an overall picture of this study indicates that the bile-adapted 242 
bifidobacteria strains were able to in vitro survive better in human gastric and duodenal juices 243 
than their original counterparts. However the bile-resistance phenotype was not related to any 244 
improvement of the in vitro adhesion capability after the GIT transit. The next step would be 245 
to check whether these in vitro findings also apply to the in vivo situation where the potential 246 
probiotics have to compete for mucosa receptors and nutrients with a plethora of intestinal 247 
microorganisms. 248 
 249 
Acknowledgements  250 
This work was financed by FEDER funds (European Union) and the Spanish “Plan 251 
Nacional de I+D+I” through projects AGL2004-6088, AGL2007-62736 and AGL2009-252 
09445. M. Fernández-García was the recipient of a Technician contract financed by the 253 
project AGL2007-62736.  Dr. T. Lesuffleur (INSERM U843 Paris, France) is acknowledged 254 
for the kindly supplying the HT29-MTX cell line.  255 
 256 
References 257 
Candela, M., Perna, F., Carnevali, P., Vitali, B., Ciati, R., Gionchetti, R., Rizzello, F., 258 
Campieri, M., Brigidi, P., 2008. Interaction of probiotic Lactobacillus and 259 
Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, 260 
competition against enteropathogens and modulation of IL-8 production. Int. J. Food 261 
Microbiol. 125, 286-292. 262 
Cencic, A., Langerholc, T. 2010. Functional cell models of the gut and their applications in 263 
food microbiology-A review. Int. J. Food Microbiol. 141, S4-S14. 264 
12 
 
 
Collado, M.C., Sanz, Y., 2006. Method for direct selection of potentially probiotic 265 
Bifidobacterium strains from human feces bases on their acid-adaptation ability. J. 266 
Microbiol. Meth. 66, 560-563. 267 
Chung, H.S., Kim, Y.B., Chun, S.L., Ji, G.E., 1999. Screening and selection of acid and bile 268 
resistant bifidobacteria. Int. J. Food Microbiol. 47, 25-32. 269 
Crawford, R.W., Gibson, D.L., Kay, W.W., Gunn, J.S., 2008. Identification of bile-induced 270 
exopolysaccharide required for Salmonella biofilm formation on gallstone surfaces. 271 
Infect. Immun. 76, 5341-5349. 272 
del Piano, M., Strozzi, P., Barba, M., Allesina, S., Deidda, F., Lorenzini, P., Morelli, L., 273 
Carmagnola, S., Pagliarulo, M., Balzarini, M., Ballarè, M., Orsello, M., Montino, F., 274 
Sartori, M., Garello, E., Capurso, L., 2008. In vitro sensitivity of probiotics to human 275 
pancreatic juice. J. Clin. Gastroenterol. 42, S170-S173. 276 
Denou, E., Pridmore, R.D., Berger, B., Panoff, J.M., Arigoni, F., Brüssow, H., 2008. 277 
Identification of genes associated with the long-gut-persistence phenotype of the 278 
probiotic Lactobacillus johnsonii strain NCC533 using a combination of genomics and 279 
transciptome analysis. J. Bacteriol. 190, 3161-3168. 280 
de Palencia, P.F., López, P., Corbi, A.L., Peláez, C., Requena, T., 2008. Probiotic strains: 281 
survival under simulated gastrointestinal conditions, in vitro adhesion to Caco-2 cells 282 
and effect on cytokine secretion. Eur. Food Res.Technol. 227, 1475-1484. 283 
FAO/WHO, 2006. Probiotics in food. Health and nutritional properties and guidelines for 284 
evaluation. FAO Food and Nutritional paper No. 85 (ISBN 92-5-105513-0). 285 
Gueimonde, M., Delgado, S., Mayo, B., Ruas-Madiedo, P., Margolles, A., de los Reyes-286 
Gavilán, C.G., 2004. Viability and diversity of probiotic Lactobacillus and 287 
Bifidobacterium populations included in commercial fermented milks. Food Res. Int. 288 
37, 839-850. 289 
13 
 
 
Gueimonde, M., Noriega, L., Margolles, A., de los Reyes-Gavilán, C.G., Salminen, S., 2005. 290 
Ability of Bifidobacterium strains with acquired resistance to bile to adhere to human 291 
intestinal mucus. Int. J. Food Microbiol. 101, 341-346. 292 
Gueimonde, M., Margolles, A., de los Reyes-Gavilán, C.G., Salminen S., 2007. Competitive 293 
exclusion of enteropathogens from human intestinal mucus by Bifidobacterium strains 294 
with acquired resistance to bile - A preliminary study. Int. J. Food Microbiol. 113, 295 
228-232. 296 
Huang, Y., Adams, M.C., 2004. In vitro assessment of the upper gastrointestinal tolerance of 297 
potential probiotic dairy propionibacteria. Int. J. Food Microbiol. 91, 253-260. 298 
Hung, D.T., Zhu, J., Sturtevant, D., Mekalanos, J.J., 2006. Bile acids stimulate biofilm 299 
formation in Vibrio cholerae. Mol. Microbiol. 59, 193-201. 300 
Lesuffleur, T., Barbat, A., Dussaulx, E., Zweibaum A., 1990. Growth adaptation to 301 
methotrexate of HT-29 human colon-carcinoma cells is associated with their ability to 302 
differentiate into columnar and mucus-secreting cells. Cancer Res. 50, 6334-6343. 303 
Mainville, I., Arcand, Y., Farnworth, E.R., 2005. A dynamic model that simulates the human 304 
upper gastrointestinal tract for the study of probiotics. Int. J. Food Microbiol. 99, 287-305 
296. 306 
Margolles, A., García, L., Sánchez, B., Gueimonde, M., de los Reyes-Gavilán, C.G., 2003. 307 
Characterization of a Bifidobacterium strain with acquired resistance to cholate - A 308 
preliminary study. Int. J. Food Microbiol. 82, 191-198. 309 
Masco, L., Huys, G., de Brandt, E., Temmerman, R., Swings J., 2005. Culture-dependent and 310 
culture-independent qualitative analysis of probiotic products claimed to contain 311 
bifidobacteria. Int. J. Food Microbiol. 102, 221-230. 312 
14 
 
 
Masco, L., Crockaert, C., van Hoorde, K., Swings J., Huys, G., 2007. In vitro assessment of 313 
the gastrointestinal transit tolerance of taxonomic reference strains from human origin 314 
and probiotic product isolated of Bifidobacterium. J. Dairy Sci. 90, 3572-3578. 315 
Mozzi, F., Gerbino, E., Font de Valdez, G., Torino M.I., 2009. Functionality of 316 
exopolysaccharides produced by lactic acid bacteria in an in vitro gastric system. J. 317 
Appl. Microbiol. 107, 56-64. 318 
Noriega, L., Gueimonde, M., Sánchez, B., Margolles, A., de los Reyes-Gavilán, C.G., 2004. 319 
Effect of the adaptation to high bile salts concentrations on glycosidic activity, 320 
survival to low pH and cross-resistance to bile salts in Bifidobacterium. Int. J. Food 321 
Microbiol. 94, 79-86. 322 
Riedel, C.U., Foata, F., Goldstein, D.R., Blum, S., Eikmanns, B.K., 2006. Interaction of 323 
bifidobacteria with Caco-2 cells- adhesion and impact on expression profiles. Int. J. 324 
Food Microbiol. 110, 62-68. 325 
Ruas-Madiedo, P., Gueimonde, M., Margolles, A., de los Reyes-Gavilán, C.G., Salminen, S., 326 
2006. Exopolysaccharides produced by probiotic strains modify the adhesion of 327 
probiotics and enteropathogenes to human intestinal mucus. J. Food Prot. 69, 2011-328 
2015. 329 
Ruas-Madiedo, P., Gueimonde, M., Arigoni, F., de los Reyes-Gavilán, C.G., Margolles, A., 330 
2009. Bile affects the synthesis of exopolysaccharides by Bifidobacterium animalis. 331 
Appl. Environ. Microbiol. 75, 1204-1207.  332 
Ruas-Madiedo, P., Medrano, M., Salazar, N., de los Reyes-Gavilán, C.G., Pérez, P.F., 333 
Abraham, A., 2010. Exopolysaccharides produced by Lactobacillus and 334 
Bifidobacterium strains abrogate in vitro the cytotoxic effect of bacterial toxins on 335 
eukaryotic cells. J. Appl. Microbiol. 109, 2079-2086. 336 
15 
 
 
Ruiz, L., Sánchez, B., Ruas-Madiedo, P., de los Reyes-Gavilán, C.G., Margolles, A., 2007. 337 
Cell envelope changes in Bifidobacterium animalis ssp. lactis as response to bile. 338 
FEMS Microbiol. Lett. 274, 316-322. 339 
Sánchez, B., Ruiz, L., de los Reyes-Gavilán, C.G., Margolles, A., 2008. Proteomics of stress 340 
response in Bifidobacterium. Front. Biosci. 13, 6905-6919.   341 
Sanchez, B., Fernández-García, M., Margolles, A., de los Reyes-Gavilán, C.G., Ruas-342 
Madiedo, P. 2010. Technological and probiotic selection criteria of a bile-adapted 343 
Bifidobacterium animalis subsp. lactis strain. Int. Dairy J. 20, 800-805.  344 
Schillinger, U., Guigas, C., Holzapfel, W.H., 2005. In vitro adherence and other properties of 345 
lactobacilli used in probiotic yoghurt-like products. Int. Dairy J. 15, 1289-1297. 346 
347 
16 
 
 
Table 1 Bifidobacterium strains used in this study 348 
Species Strains a Origin 
B. animalis subsp. lactis IPLA4549 (P) 
4549dOx (D) 
IPLA collection b 
IPLA collection  
B. animalis subsp. lactis A1 (P) 
A1dOx (D) 
A1dOx-R1 (D) 
Isolated from commercial dairy product 
IPLA collection 
IPLA collection 
B. longum NB667 (P) 
667Co (D) 
NIZO Culture collection (infant faeces) c 
IPLA collection 
a Parental (P) and bile-adapted derivative (D) strains 349 
b Isolated as a co-culture of the strain B. bifidum CECT4549 (10). 350 
c NIZO Food Research Collection (Ede, The Netherlands)  351 
352 
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Legends to figures  353 
Fig 1.  Schematic representation of the simulated gastrointestinal transit using juices of 354 
human origin. GJ: gastric juice (step 1), DJ: duodenal juice (step 2), dDJ-18h: duodenal juice 355 
diluted 1/10 with saline solution after 18 h of incubation (step 3). 356 
 357 
Fig 2. Counts (log cfu mL-1) along the simulated gastrointestinal transit using juices of human 358 
origin of parental (white circles) and bile-resistant derivatives (black symbols) 359 
Bifidobacterium strains initially suspended in 20% skimmed milk. GJ: gastric juice (step 1), 360 
DJ: duodenal juice (step 2), dDJ-18h: duodenal juice diluted 1/10 with saline solution after 18 361 
h of incubation (step 3). The coefficient of variation (SD / mean) percentage of this data 362 
varied among 0.5 and 10%. At the end of the challenge (dDJ-18 h), symbols that do not share 363 
a common letter indicating that counts are statistically different (p<0.05).  364 
 365 
Fig 3. Percentage of bacterial survival after the gastric and duodenal juice challenges (step 2) 366 
determined by the Live/Dead® BacLight kit. For each group of parental /derivative strains, 367 
the columns that do not share a common letter are statistically different (p<0.05).  368 
 369 
Fig 4. Percentage of adhesion to the epithelial cell line HT29-MTX of Bifidobacterium strains 370 
not submitted to the gastrointestinal tract challenge (a) and after the simulated gastrointestinal 371 
transit (step 3) using juices of human origin (b). Units: CFU ml-1 of adhered with respect to 372 
CFU ml-1 of added bacteria determined by plating in agar-MRSC (a), and number  mL-1 of 373 
adhered bacteria with respect to number ml-1 of added bacteria determined under optical 374 
microscope by using a Neubauer counting chamber (b). For each group of parental /derivative 375 
strains, the columns that do not share a common letter are statistically different (p<0.05). 376 
377 
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Figure 3 382 
% survival
a
b
b
b
a
a
a
0
20
40
60
80
100
B. animalis B. animalis B. longum
IPLA4549 4549dOx A1 A1dOx A1dOx-R1 NB667 667Co
383 
21 
 
 
Figure 4 384 
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